Variations of Prevalence and Incidence of Atrial Fibrillation and Oral Anticoagulation Rate According to Different Analysis Approaches

被引:0
|
作者
Pil-Sung Yang
Soorack Ryu
Daehoon Kim
Eunsun Jang
Hee Tae Yu
Tae-Hoon Kim
Jinseub Hwang
Boyoung Joung
Gregory Y. H. Lip
机构
[1] CHA University,Department of Cardiology, CHA Bundang Medical Center
[2] Daegu University,Department of Computer Science and Statistics
[3] Yonsei University Health System,Division of Cardiology, Department of Internal Medicine
[4] University of Birmingham,Institute of Cardiovascular Sciences
来源
Scientific Reports | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The reported incidence and prevalence of atrial fibrillation (AF) has been inconsistent across published studies. Using the National Health Insurance Service database of Korea, the prevalence and incidence of AF, and oral anticoagulation (OAC) use of AF patients were explored according to three different approaches; ‘formal approach’, considering individual AF diagnosis and mortality; ‘limited diagnosis approach’, using upper 5 main diagnosis; and ‘medical use approach’, using the number of medical use AF population by year without considering individual AF history and mortality. The AF prevalence progressively increased by 2.46-fold from 0.50% in 2004 to 1.54% in 2015 when using a ‘formal approach’ (p for trend <0.001). The overall prevalence was 1.09% and 0.97% when using a ‘formal approach’ and ‘limited diagnosis approaches’, respectively. Overall prevalence decreased to 0.52% with a ‘medical use approach’. The trend of annual AF incidence was stable when using a ‘formal approach’, but increased by 15% when using a ‘medical use approach’. OAC rate in 2015 was 2.1 times higher when using a ‘medical use approach’ compared to using a ‘formal approach’ (40.3% vs. 19.1%, p < 0.001). Given the wide variability in prevalence and incidence figures with different analysis approaches, careful attention to the analysis methodology is needed.
引用
收藏
相关论文
共 50 条
  • [31] Thromboembolic risk and oral anticoagulation in subclinical atrial fibrillation
    Wegner, Felix K.
    Eckardt, Lars
    TRENDS IN CARDIOVASCULAR MEDICINE, 2025, 35 (01) : 1 - 7
  • [32] Oral anticoagulation in chronic kidney disease with atrial fibrillation
    Exposito, Victor
    Seras, Miguel
    Fernandez-Fresnedo, Gema
    MEDICINA CLINICA, 2015, 144 (10): : 452 - 456
  • [33] Atrial fibrillation, hip fracture, and oral anticoagulation therapy
    Wong, Christopher X.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : 260 - 260
  • [34] COSTS AND CONSEQUENCES OF ORAL ANTICOAGULATION IN ATRIAL FIBRILLATION IN COLOMBIA
    Rosselli, D.
    Rueda, J. D.
    Garcia, A. A.
    Rodriguez-Morales, A. J.
    Garrido Lecca, S.
    Vargas Zea, N.
    Mould, J. F.
    Donato, B. M. K.
    Juarez Garcia, A.
    VALUE IN HEALTH, 2013, 16 (07) : A702 - A702
  • [35] Interdisciplinary aspects of oral anticoagulation with NOACs in atrial fibrillation
    Duerschmied, Daniel
    Bode, Christoph
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 : S1 - S1
  • [36] Stroke Prevention in Atrial Fibrillation The Role of Oral Anticoagulation
    Mtwesi, Viwe
    Amit, Guy
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (05) : 847 - +
  • [37] Atrial fibrillation and oral anticoagulation in older adults: an update
    Masoli, Jane A. H.
    Kirkham, Frances A.
    Rajkumar, Chakravarthi
    AGE AND AGEING, 2021, 50 (03) : 687 - 689
  • [39] Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation
    Galea, Roberto
    Seiffge, David
    Raeber, Lorenz
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [40] Oral anticoagulation in chronic kidney disease with atrial fibrillation
    Gomez-Fernandez, Pablo
    Martin Santana, Antonio
    Juan de Dios Arjona Barrionuevo, Y.
    NEFROLOGIA, 2021, 41 (02): : 137 - 153